Login to Your Account

AMT Gets $3.2M Runway, Aims For Hemophilia Gene Therapy

By Nuala Moran
BioWorld International Correspondent

Wednesday, January 4, 2012

LONDON – The venture capital investors in Amsterdam Molecular Therapeutics (AMT) have thrown it a €2.5 million (US$3.2 million) lifeline in the hope that will enable the company to stay solvent long enough to close a deal for its gene therapy treatment for hemophilia B.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription